Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 3753-3764

  Ramani, Karthik ^a,b   Purohit, Vivek ^a,c   Miclea, Razvan ^a,d   Gaitonde, Puneet ^a   Straubinger, Robert M ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Biocon Limited   (India)

^c Eurand Inc   (United States)

^d AMGEN INC   (United States)

Author keywords

Hemophilia A; Immunogenicity; Inhibitory antibodies; PEGylated liposomes; Recombinant FVIII

Indexed keywords

LIPOSOME; MACROGOL; RECOMBINANT ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; FEMALE; HEMOPHILIA A; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN;

EID: 53549099372     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21266     Document Type: Article

References (43)

1. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antonarakis SE, Coopar DN. 1994. Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 22:4851-4868.
2. Larner AJ. 1987. The molecular pathology of haemophilia. Q J Med 63:473-491.
3. Lenting PJ, van Mourik JA, Mertens K. 1998. The life cycle of coagulation factor VIII in view of its structure and function. Blood 92:3983-3996.
4. Klinge J, Ananyeva NM, Hauser CA, Saenko EL. 2002. Hemophilia A - From basic science to clinical practice. Semin Thromb Hemost 28:309-322.
5. Fijnvandraat K, Bril WS, Voorberg J. 2003. Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost 29:61-68.
6. Lollar P. 2002. Molecular characterization of the immune response to factor VIII. Vox Sang 83:403-408.
7. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, Shima M, Ovanesov MV, Khrenov AV, Saenko EL. 2004. Inhibitors in hemophilia A: Mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 15:109-124.
8. Ho AY, Height SE, Smith MP. 2000. Immune tolerance therapy for haemophilia. Drugs 60:547-554.
9. Foster PA, Zimmerman TS. 1989. Factor VIII structure and function. Blood Rev 3:180-191.
10. Fay PJ. 1993. Factor VIII structure and function. Thromb Haemost 70:63-67.
11. Scandella D, Mattingly M, de Graaf S, Fulcher CA. 1989. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74:1618-1626.
12. Lollar P. 1997. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost 78:647-651.
13. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P. 1995. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270:14505-14509.
14. Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P. 1997. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 272:30191-30195.
15. Fay PJ, Scandella D. 1999. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 274:29826-29830.
16. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. 1998. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 92:136-142.
17. Healey JF, Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P. 1998. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 92:3701-3709.
18. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. 1995. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86:1811-1819.
19. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. 2003. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 1:1777-1784.
20. Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW. 2004. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 92:522-528.
21. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
22. Baru M, Leo CG, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J. 2005. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb Haemost 93:1061-1068.
23. Sou K, Endo T, Takeoka S, Tsuchida E. 2000. Poly (ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug Chem 11:372-379.
24. Bartlett GR. 1959. Phosphorus assay in column chromatography. J Biol Chem 234:466-468.
25. Purohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. 2003. Topology of factor VIII bound to phosphatidylserine-contain-ing model membranes. Biochim Biophys Acta 1617: 31-38.
26. Heath TD, Macher BA, Papahadjopoulos D. 1981. Covalent attachment of immunoglobulins to liposomes via glycosphingolipids. Biochim Biophys Acta 640:66-81.
27. Over J. 1984. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl 41: 13-24.
28. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 2002. 3-Dimensional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 99:1215-1223.
29. Purohit VS, Ramani K, Sarkar R, Kazazian HH, Balasubramanian SV. 2005. Lower inhibitor development in Hemophilia A mice following administration of recombinant Factor VIII-O- Phospho-L-serine complex. J Biol Chem 280: 17593-17600.
30. Nedelman JR, Gibiansky E, Lau DT. 1995. Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 12:124-128.
31. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. 1999. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 402:439-442.
32. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. 2000. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 84:826-832.
33. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM. 2001. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 85:125-133.
34. White GC II, Kempten CL, Grimsley A, Nielsen B, Roberts HR. 2005. Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 3:1676-1681.
35. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. 2002. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88:568-575.
36. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740, discussion 1719.
37. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-162.
38. Lenting PJ, Neels JG, van den Berg BM, Clijsters PP, Meijerman DW, Pannekoek H, van Mourik JA, Mertens K, van Zonneveld AJ. 1999. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 274:23734-23739.
39. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. 1999. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 274: 37685-37692.
40. Klibanov AL, Maruyama K, Torchilin VP, Huang L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237.
41. Chiu GN, Bally MB, Mayer LD. 2001. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510:56-69.
42. Li WM, Mayer LD, Bally MB. 2002. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300:976-983.
43. Gilbert GE, Arena AA. 1995. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-ser-ine. J Biol Chem 270:18500-18505.